Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Evorpacept + ZW25 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Evorpacept | ALX-148|ALX 148|ALX148 | CD47 Antibody 31 Immune Checkpoint Inhibitor 149 | Evorpacept (ALX148) is a chimeric protein consisting of the Fc region of immunoglobulin fused to the CD47 SIRPa-binding domain, that blocks the ability of CD47 to bind SIRPa on macrophages thereby promoting phagocytosis of tumor cells (PMID: 28286286), and may also stimulate cytotoxic T-cells (PMID: 29873856). | |
ZW25 | ZW-25|Zanidatamab | HER2 (ERBB2) Antibody 76 | Zanidatamab (ZW25) is a bispecific antibody targeting ERBB2 (HER2), which induces anti-tumor immune response against Erbb2 (Her2)-expressing tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P, PMID: 32054397). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05027139 | Phase Ib/II | Evorpacept + ZW25 | A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer | Active, not recruiting | USA | 0 |